Embera NeuroTherapeutics Announces Positive Topline Data from Phase 1b Cocaine Interaction Study of EMB-001

Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for cocaine, nicotine, and other addictions, today announced that EMB-001 was found to be well-tolerated in a Phase 1b cocaine interaction study, and no new safety signals were observed.

Embera NeuroTherapeutics Receives $11M Grant from National Institute on Drug Abuse for the Clinical Development of EMB-001 for the treatment of Cocaine Addiction

Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for cocaine, nicotine, and other addictions, today announced that it has received an $11.1 million, three-year grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH). The grant will support continued clinical development of EMB-001 for the treatment of cocaine addiction, which is clinically termed “cocaine use disorder.”

Embera NeuroTherapeutics Announces Successful Completion of Phase 1 Clinical Trial Testing EMB-001, a Potential Novel Treatment for Addictions

Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for cocaine use disorder, smoking cessation, and other addictions, today announced that EMB-001 met the primary endpoints of safety and tolerability in a Phase 1 clinical trial. Embera also announced that the Company’s Chief Executive Officer, Robert Linke and Chief Medical Officer, Dr. Michael Detke, will present at the Biotech Showcase on Monday, January 11, 2016 at 2:30pm in San Francisco, California.

Embera NeuroTherapeutics Initiates Phase 1 Clinical Trial to Test EMB-001 as a Novel Treatment for Addictions

Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for smoking cessation, cocaine use disorder and other addictions, today announced the first subject received the initial dose in a Phase 1 clinical trial evaluating EMB-001. A novel combination of the FDA-approved drugs metyrapone and oxazepam, EMB-001 is being investigated for the potential treatment of cocaine use disorder and other addictions such as tobacco and methamphetamine use disorders.

Embera NeuroTherapeutics Secures A-2 Financing to Advance EMB-001 for Addictions Through Phase 1 Clinical Trial

Embera NeuroTherapeutics, Inc., a specialty biopharmaceutical company developing novel treatments for smoking cessation, cocaine use disorder and other addictions, today announced that it raised $1.9 million in Series A-2 financing. The funding enables the Company to complete a Phase 1, combined single and multiple rising dose clinical trial evaluating the safety and pharmacokinetics of EMB-001 in volunteers who smoke cigarettes but are otherwise healthy.

Embera NeuroTherapeutics and Collaborators Publish Paper in Psychopharmacology Supporting Its Novel Drug Combination, EMB-001, for Smoking Cessation

Embera NeuroTherapeutics Inc., a specialty pharmaceutical company developing novel treatments for smoking cessation and other addictions, announced today the publication of results from a preclinical study of the combination use of metyrapone and oxazepam to treat nicotine addictions. Metyrapone and oxazepam, both of which are FDA-approved drugs, comprise EMB-001, Embera’s lead pipeline candidate. Researchers found that at the lowest doses tested, the combination more effectively reduced nicotine intake than did either drug alone.

Embera NeuroTherapeutics Closes on $4.5 Million Continuation of Series A Financing

Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for smoking cessation and other addictions, announced today that it has closed on $4.5 million in a continuation of its Series A financing. Embera’s existing venture investors, Louisiana Ventures, L.P., Louisiana Fund I, and Themelios Ventures, as well as private investors, participated in the round. Proceeds from this financing, combined with development grant funding from the National Institute for Drug Abuse, will support clinical development of EMB-001 through a Phase 1 safety study, enabling Embera’s clinical development programs for both smoking cessation and cocaine dependence.

Embera NeuroTherapeutics’ Lead Candidate, EMB-001, Supported by $3.9M Grant from National Institute on Drug Abuse

Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for addiction and obesity, announced today that the Louisiana State University Health Sciences Center (LSUHSC-S) has received a $3.9 million dollar grant from the National Institute on Drug Abuse (NIDA). The grant will support the next stages of development for Embera’s drug candidate EMB-001 to treat cocaine dependence, as well as advance EMB-001 into clinical testing. Work done under this grant will also support Embera’s clinical development program for EMB-001 for smoking cessation.